Background
Methods
Study design
Definitions of statin intolerance
Measurement of cardiac biomarker
Clinical outcomes
Statistical analysis
Results
Baseline characteristics
All N = 952 | Statin Intolerance N = 138 | No Statin Intolerance N = 814 | P-value | |
---|---|---|---|---|
Age, years | 66 ± 11 | 67 ± 10 | 66 ± 11 | 0.79 |
Age ≥ 65 years, n (%) | 558 (58.6) | 81 (58.7) | 477 (58.6) | 0.98 |
Male, n (%) | 696 (73.1) | 99 (71.7) | 597 (73.3) | 0.70 |
Current smoker, n (%) | 160 (16.8) | 25 (18.1) | 135 (16.6) | 0.66 |
Hypertension, n (%) | 716 (75.2) | 107 (77.5) | 609 (74.8) | 0.49 |
Diabetes mellitus, n (%) | 336 (35.3) | 61 (44.2) | 275 (33.8) | 0.02 |
Type of statin at baseline | ||||
Simvastatin, n (%) | 537 (56.4) | 82 (59.4) | 455 (55.9) | 0.50 |
Atorvastatin, n (%) | 179 (18.8) | 21 (15.2) | 158 (19.4) | |
Rosuvastatin, n (%) | 236 (24.8) | 35 (25.4) | 201 (24.7) | |
Statin dose at baseline (simvastatin dose equivalent) | ||||
10 mg, n (%) | 227 (23.8) | 30 (21.7) | 197 (24.2) | 0.91 |
20 mg, n (%) | 365 (38.3) | 56 (40.6) | 309 (38.0) | |
40 mg, n (%) | 254 (26.7) | 36 (26.1) | 218 (26.8) | |
80 mg, n (%) | 106 (11.1) | 16 (11.6) | 90 (11.1) | |
Baseline lipid profile* | ||||
Total cholesterol, mmol/L | 4.1 ± 1.0 | 4.2 ± 1.1 | 4.0 ± 1.0 | 0.08 |
Triglyceride, mmol/L | 1.5 ± 1.0 | 1.7 ± 1.2 | 1.5 ± 1.0 | < 0.01 |
HDL-C, mmol/L | 1.2 ± 0.4 | 1.2 ± 0.5 | 1.2 ± 0.3 | 0.78 |
LDL-C, mmol/L | 2.1 ± 0.8 | 2.2 ± 0.9 | 2.1 ± 0.8 | 0.71 |
LDL-C < 1.8 mmol/L, n (%) | 359 (37.7) | 49 (35.5) | 310 (38.1) | 0.56 |
Non-HDL-C, mmol/L | 2.9 ± 1.0 | 3.0 ± 1.0 | 2.8 ± 1.0 | 0.09 |
Ln hs-cTnI, pg/ml | 2.2 ± 1.4 | 2.6 ± 1.6 | 2.1 ± 1.3 | < 0.01 |
Type of statin at follow-up | ||||
Simvastatin, n (%) | 626 (65.8) | 93 (67.4) | 533 (65.5) | 0.41 |
Atorvastatin, n (%) | 145 (15.2) | 16 (11.6) | 129 (15.9) | |
Rosuvastatin, n (%) | 181 (19.0) | 29 (21.0) | 152 (18.7) | |
Statin dose at follow-up (simvastatin dose equivalent) | ||||
10 mg, n (%) | 280 (29.4) | 39 (28.3) | 241 (29.6) | 0.84 |
20 mg, n (%) | 378 (39.7) | 55 (39.9) | 323 (39.7) | |
40 mg, n (%) | 203 (21.3) | 28 (20.3) | 175 (21.5) | |
80 mg, n (%) | 91 (9.6) | 16 (11.6) | 75 (9.2) | |
Other lipid lowering therapy at follow-up | ||||
Ezetimible, n (%) | 32 (3.4) | 8 (5.8) | 24 (3.0) | 0.09 |
Fibrate, n (%) | 82 (8.6) | 14 (10.1) | 68 (8.4) | 0.49 |
Lipid profile at follow-up | ||||
Total cholesterol, mmol/L | 3.7 ± 0.8 | 3.9 ± 1.0 | 3.7 ± 0.7 | < 0.01 |
Triglyceride, mmol/L | 1.4 ± 0.9 | 1.6 ± 1.1 | 1.3 ± 0.8 | < 0.01 |
HDL-C, mmol/L | 1.2 ± 0.4 | 1.2 ± 0.4 | 1.2 ± 0.4 | 0.09 |
LDL-C, mmol/L | 1.9 ± 0.6 | 2.0 ± 0.8 | 1.9 ± 0.6 | 0.01 |
LDL-C < 1.8 mmol/L, n (%) | 412 (43.3) | 51 (37.0) | 361 (44.4) | 0.11 |
Non-HDL-C, mmol/L | 2.5 ± 0.7 | 2.7 ± 0.9 | 2.5 ± 0.7 | < 0.01 |
Clinical outcomes
With MACE N = 148 | Without MACE N = 804 | P-value | |
---|---|---|---|
Age, years | 72 ± 9 | 66 ± 11 | < 0.01 |
Age ≥ 65 years, n (%) | 120 (81) | 438 (54) | < 0.01 |
Male, n (%) | 98 (66) | 598 (74) | 0.040 |
Current smoker, n (%) | 29 (20) | 131 (16) | 0.32 |
Hypertension, n(%) | 129 (87) | 587 (73) | < 0.01 |
Diabetes mellitus, n (%) | 86 (51) | 260 (32) | < 0.01 |
Baseline lipid profile* | |||
Total cholesterol, mmol/L | 4.2 ± 1.1 | 4.0 ± 1.0 | 0.17 |
Triglyceride, mmol/L | 1.5 ± 1.0 | 1.5 ± 1.0 | 0.71 |
HDL-C, mmol/L | 1.2 ± 0.5 | 1.2 ± 0.3 | 0.51 |
LDL-C, mmol/L | 2.2 ± 1.0 | 2.1 ± 0.8 | 0.13 |
LDL-C < 1.8 mmol/L, n (%) | 56 (37.8) | 303 (37.7) | 0.97 |
Non-HDL-C, mmol/L | 3.0 ± 1.1 | 2.8 ± 1.0 | 0.10 |
Follow-up lipid profile | |||
Total cholesterol, mmol/L | 3.7 ± 0.8 | 3.8 ± 0.8 | 0.17 |
Triglyceride, mmol/L | 1.4 ± 0.9 | 1.4 ± 0.9 | 0.86 |
HDL-C, mmol/L | 1.2 ± 0.4 | 1.2 ± 0.4 | 0.16 |
LDL-C, mmol/L | 1.9 ± 0.7 | 1.9 ± 0.6 | 0.65 |
LDL-C < 1.8 mmol/L, n (%) | 69 (46.6) | 343 (42.7) | 0.37 |
Non-HDL-C, mmol/L | 2.5 ± 0.7 | 2.5 ± 0.7 | 0.45 |
Statin intolerance, n (%) | 41 (27.7) | 97 (12.1) | < 0.01 |
Ln hs-cTnI, pg/ml | 3.1 ± 1.6 | 2.0 ± 1.2 | < 0.01 |
HR (95% CI) | P-value | |
---|---|---|
Age ≥ 65 years | 2.72 (1.79–4.15) | < 0.01 |
Hypertension | 1.37 (0.83–2.27) | 0.22 |
Diabetes mellitus | 1.26 (0.90–1.77) | 0.18 |
hs-cTnI | 3.18 (2.07–4.89) | < 0.01 |
Statin intolerance | 1.52 (1.06–2.19) | 0.024 |
Effect of hs-cTnI level on MACE
hs-cTnl below cut-off | hs-cTnl above cut-off | |||
---|---|---|---|---|
HR (95% CI) | P-value | HR (95% CI) | P-value | |
Age ≥ 65 | 2.70 (1.15–6.34) | 0.022 | 2.75 (1.69–4.47) | < 0.01 |
Hypertension | 1.26 (0.49–3.24) | 0.63 | 1.44 (0.79–2.63) | 0.24 |
Diabetes | 1.05 (0.47–2.36) | 0.90 | 1.29 (0.89–1.87) | 0.19 |
Statin intolerance | 1.40 (0.55–3.52) | 0.48 | 1.51 (1.01–2.24) | 0.044 |